Cyclacel Pharmaceuticals (CYCCP) 6.47 $CYCCP
Cyclacel Pharmaceuticals to Present at the 17th Annual BIO CEO & Investor Conference
GlobeNewswire - Tue Feb 03, 6:13AM CST
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company"
, a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today announced that the Company will present at the 17th Annual BIO CEO & Investor Conference, being held at the Waldorf Astoria Hotel in New York, New York. Spiro Rombotis, President and Chief Executive Officer, will provide an overview of the Company and its progress in key programs on Tuesday, February 10, 2015 at 10:00 a.m. EST in the Conrad room.
CYCC: 0.62 (-0.01), CYCCP: 6.47 (-0.22)
Cyclacel Pharmaceuticals to Present at the Biotech Showcase(TM) 2015 Conference
GlobeNewswire - Tue Jan 06, 6:00AM CST
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) "Cyclacel" or the "Company" , a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today announced that the Company will present at the Biotech Showcase 2015 conference being held at Parc 55 Wyndham San Francisco - Union Square in San Francisco, California. Spiro Rombotis, President and Chief Executive Officer, will provide an overview of the Company and its progress in key programs at 3:30 p.m. PST on Monday, January 12, 2015.
CYCC: 0.62 (-0.01), CYCCP: 6.47 (-0.22)
Cyclacel Announces Enrollment of 486 Patients, DSMB Recommendations and That the Seamless Phase 3 Trial of Sapacitabine in AML Will Continue to Final Analysis
GlobeNewswire - Tue Dec 16, 6:00AM CST
- DSMB determined that the planned futility boundary has been crossed; but saw no reason for patients to discontinue from study -
CYCC: 0.62 (-0.01), CYCCP: 6.47 (-0.22)
Cyclacel Pharmaceuticals Reports Third Quarter 2014 Financial Results
GlobeNewswire - Tue Nov 11, 3:05PM CST
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company" , a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today reported its financial results and business highlights for the third quarter ended September 30, 2014.
CYCC: 0.62 (-0.01), CYCCP: 6.47 (-0.22)
Cyclacel Pharmaceuticals to Release 2014 Third Quarter Financial Results
GlobeNewswire - Tue Nov 04, 6:00AM CST
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company" , a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, will announce financial results for the third quarter ended September 30, 2014 on Tuesday, November 11, 2014. The Company will host a conference call and live webcast at 4:30 pm Eastern time on the same day.
CYCC: 0.62 (-0.01), CYCCP: 6.47 (-0.22)
Cyclacel Announces Data Safety Monitoring Board Recommendation to Continue the Seamless Phase 3 Trial of Sapacitabine in AML
GlobeNewswire - Thu Oct 09, 6:08AM CDT
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders today announced that the independent Data and Safety Monitoring Board (DSMB) for the Company's Phase 3 SEAMLESS study in acute myeloid leukemia (AML) has completed its fourth planned safety review and recommended that the study should continue as planned without any modifications. The DSMB reviewed available data from 317 randomized patients with at least 60 days of follow-up and noted that no safety or efficacy concerns were identified.
CYCC: 0.62 (-0.01), CYCCP: 6.47 (-0.22)
FXA, GOODO, CLMS, SLW, LMAT, CYCCP Are Seasonally Ripe To Go Down In the Next Five Weeks
M2 - Tue Sep 30, 3:32AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of CurrencyShares Australian Dollar Trust (NYSE:FXA), Gladstone Commercial Corp (NASDAQ:GOODO), Calamos Asset Management Inc (NASDAQ:CLMS), Silver Wheaton Corp (NYSE:SLW), LeMaitre Vascular Inc (NASDAQ:LMAT), Cyclacel Pharmaceuticals Inc (NASDAQ:CYCCP) and each have a high seasonal probability to go Down in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
CLMS: 12.96 (-0.08), CYCC: 0.62 (-0.01), FXA: 77.69 (+0.23), LMAT: 7.66 (+0.08), GOOD: 17.39 (-0.09), SLW: 22.76 (+0.34), CYCCP: 6.47 (-0.22), GOODO: 25.65 (-0.53)
Cyclacel to Present at BioCentury's Newsmakers in the Biotech Industry Conference
GlobeNewswire - Fri Sep 19, 6:00AM CDT
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company" , a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today announced that the Company will present at BioCentury's Newsmakers in the Biotech Industry Conference being held at the Millennium Broadway Hotel & Conference Center, New York, NY. Spiro Rombotis, President & Chief Executive Officer, will provide an overview of the Company and its progress in key programs at 3:30 pm EDT on Friday September 26, 2014.
CYCC: 0.62 (-0.01), CYCCP: 6.47 (-0.22)
Cyclacel's CYC065 CDK Inhibitor Demonstrates Therapeutic Potential in Acute Leukemias With Mixed Lineage Leukemia (MLL) Rearrangements
GlobeNewswire - Thu Sep 18, 6:00AM CDT
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company" , today announced the presentation of preclinical data demonstrating the therapeutic potential of CYC065, Cyclacel's second-generation cyclin dependent kinase (CDK) inhibitor, to treat acute leukemias, and in particular those with rearrangements in the mixed lineage leukemia (MLL) gene. The data showed that in vitro all human acute myelogenous leukemia (AML) and acute lymphocytic leukemia (ALL) cell lines with MLL rearrangements (MLLr) tested were sensitive to CYC065 and that the drug inhibited MLL-driven gene expression. Potent anticancer activity of CYC065 was demonstrated in vivo in AML xenograft models resulting in over 90% inhibition of tumor growth. The data were presented at the 2014 Society of Hematologic Oncology (SOHO) meeting taking place September 17-20, 2014 in Houston, Texas.
CYCC: 0.62 (-0.01), CYCCP: 6.47 (-0.22)
Cyclacel Pharmaceuticals hires Dr Samuel L. Barker to board
M2 - Fri Sep 12, 7:51AM CDT
Biopharmaceutical company Cyclacel Pharmaceuticals (NasdaqGM:CYCC) (NasdaqCM:CYCCP) said on Thursday that it has elected Dr Samuel L. Barker, PhD to its board of directors.
CYCC: 0.62 (-0.01), CYCCP: 6.47 (-0.22)
Cyclacel Pharmaceuticals Appoints Samuel L. Barker, Ph.D., to Board of Directors
GlobeNewswire - Thu Sep 11, 6:00AM CDT
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company" announced today the appointment of Samuel L. Barker, Ph.D., to its Board of Directors.
CYCC: 0.62 (-0.01), CYCCP: 6.47 (-0.22)
Cyclacel Announces Abstract Selected for Presentation at Society of Hematologic Oncology Annual Meeting
GlobeNewswire - Wed Sep 10, 6:08AM CDT
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company" , a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, announced that an abstract highlighting the therapeutic potential of CYC065, the Company's novel, orally available, second generation cyclin-dependent kinase (CDK) inhibitor, in acute myeloid leukaemia (AML) and mixed-lineage leukaemia (MLL), has been selected for presentation at the Society of Hematologic Oncology (SOHO) annual meeting, taking place September 17-20, 2014 at the Hilton Americas Hotel in Houston, Texas.
CYCC: 0.62 (-0.01), CYCCP: 6.47 (-0.22)
Cyclacel Pharmaceuticals to Present at 16th Rodman & Renshaw Annual Global Investment Conference
GlobeNewswire - Tue Sep 02, 6:10AM CDT
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company" , a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders today announced that the Company will present at the 16 Rodman & Renshaw Annual Global Investment Conference being held at the New York Palace Hotel, New York, NY. Spiro Rombotis, President & Chief Executive Officer, will provide an overview of the Company and its progress in key programs at 10:25 am EDT on Tuesday September 9, 2014.
CYCC: 0.62 (-0.01), CYCCP: 6.47 (-0.22)
Cyclacel Pharmaceuticals Reports Second Quarter 2014 Financial Results
GlobeNewswire - Tue Aug 12, 4:41PM CDT
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company" , a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today reported its financial results and business highlights for the second quarter ended June 30, 2014.
CYCC: 0.62 (-0.01), CYCCP: 6.47 (-0.22)
Cyclacel Pharmaceuticals to Release 2014 Second Quarter Financial Results
GlobeNewswire - Wed Aug 06, 6:00AM CDT
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company" , a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, will announce financial results for the second quarter ended June 30, 2014 on Tuesday, August 12, 2014. The Company will host a conference call and live webcast at 4:30 pm Eastern time on the same day.
CYCC: 0.62 (-0.01), CYCCP: 6.47 (-0.22)
Cyclacel Pharmaceuticals to Present at 9th Annual JMP Securities Healthcare Conference
GlobeNewswire - Tue Jun 17, 3:05PM CDT
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company" , a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders today announced that the Company will present at the 9 Annual JMP Securities Healthcare Conference being held at The Westin New York Grand Central, New York City. Paul McBarron, Executive Vice President, Finance and Chief Operating Officer, will provide an overview of the Company and its progress in key programs at 11:00 a.m. EDT on Tuesday, June 24, 2014.
CYCC: 0.62 (-0.01), CYCCP: 6.47 (-0.22)
Cyclacel Pharmaceuticals to Present at the 17th Annual BIO CEO & Investor Conference
GlobeNewswire - Tue Feb 03, 6:13AM CST
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company"
, a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today announced that the Company will present at the 17th Annual BIO CEO & Investor Conference, being held at the Waldorf Astoria Hotel in New York, New York. Spiro Rombotis, President and Chief Executive Officer, will provide an overview of the Company and its progress in key programs on Tuesday, February 10, 2015 at 10:00 a.m. EST in the Conrad room. CYCC: 0.62 (-0.01), CYCCP: 6.47 (-0.22)
Cyclacel Pharmaceuticals to Present at the Biotech Showcase(TM) 2015 Conference
GlobeNewswire - Tue Jan 06, 6:00AM CST
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) "Cyclacel" or the "Company"
, a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today announced that the Company will present at the Biotech Showcase 2015 conference being held at Parc 55 Wyndham San Francisco - Union Square in San Francisco, California. Spiro Rombotis, President and Chief Executive Officer, will provide an overview of the Company and its progress in key programs at 3:30 p.m. PST on Monday, January 12, 2015. CYCC: 0.62 (-0.01), CYCCP: 6.47 (-0.22)
Cyclacel Announces Enrollment of 486 Patients, DSMB Recommendations and That the Seamless Phase 3 Trial of Sapacitabine in AML Will Continue to Final Analysis
GlobeNewswire - Tue Dec 16, 6:00AM CST
- DSMB determined that the planned futility boundary has been crossed; but saw no reason for patients to discontinue from study -
CYCC: 0.62 (-0.01), CYCCP: 6.47 (-0.22)
Cyclacel Pharmaceuticals Reports Third Quarter 2014 Financial Results
GlobeNewswire - Tue Nov 11, 3:05PM CST
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company"
, a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today reported its financial results and business highlights for the third quarter ended September 30, 2014. CYCC: 0.62 (-0.01), CYCCP: 6.47 (-0.22)
Cyclacel Pharmaceuticals to Release 2014 Third Quarter Financial Results
GlobeNewswire - Tue Nov 04, 6:00AM CST
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company"
, a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, will announce financial results for the third quarter ended September 30, 2014 on Tuesday, November 11, 2014. The Company will host a conference call and live webcast at 4:30 pm Eastern time on the same day. CYCC: 0.62 (-0.01), CYCCP: 6.47 (-0.22)
Cyclacel Announces Data Safety Monitoring Board Recommendation to Continue the Seamless Phase 3 Trial of Sapacitabine in AML
GlobeNewswire - Thu Oct 09, 6:08AM CDT
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders today announced that the independent Data and Safety Monitoring Board (DSMB) for the Company's Phase 3 SEAMLESS study in acute myeloid leukemia (AML) has completed its fourth planned safety review and recommended that the study should continue as planned without any modifications. The DSMB reviewed available data from 317 randomized patients with at least 60 days of follow-up and noted that no safety or efficacy concerns were identified.
CYCC: 0.62 (-0.01), CYCCP: 6.47 (-0.22)
FXA, GOODO, CLMS, SLW, LMAT, CYCCP Are Seasonally Ripe To Go Down In the Next Five Weeks
M2 - Tue Sep 30, 3:32AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of CurrencyShares Australian Dollar Trust (NYSE:FXA), Gladstone Commercial Corp (NASDAQ:GOODO), Calamos Asset Management Inc (NASDAQ:CLMS), Silver Wheaton Corp (NYSE:SLW), LeMaitre Vascular Inc (NASDAQ:LMAT), Cyclacel Pharmaceuticals Inc (NASDAQ:CYCCP) and each have a high seasonal probability to go Down in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
CLMS: 12.96 (-0.08), CYCC: 0.62 (-0.01), FXA: 77.69 (+0.23), LMAT: 7.66 (+0.08), GOOD: 17.39 (-0.09), SLW: 22.76 (+0.34), CYCCP: 6.47 (-0.22), GOODO: 25.65 (-0.53)
Cyclacel to Present at BioCentury's Newsmakers in the Biotech Industry Conference
GlobeNewswire - Fri Sep 19, 6:00AM CDT
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company"
, a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today announced that the Company will present at BioCentury's Newsmakers in the Biotech Industry Conference being held at the Millennium Broadway Hotel & Conference Center, New York, NY. Spiro Rombotis, President & Chief Executive Officer, will provide an overview of the Company and its progress in key programs at 3:30 pm EDT on Friday September 26, 2014. CYCC: 0.62 (-0.01), CYCCP: 6.47 (-0.22)
Cyclacel's CYC065 CDK Inhibitor Demonstrates Therapeutic Potential in Acute Leukemias With Mixed Lineage Leukemia (MLL) Rearrangements
GlobeNewswire - Thu Sep 18, 6:00AM CDT
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company"
, today announced the presentation of preclinical data demonstrating the therapeutic potential of CYC065, Cyclacel's second-generation cyclin dependent kinase (CDK) inhibitor, to treat acute leukemias, and in particular those with rearrangements in the mixed lineage leukemia (MLL) gene. The data showed that in vitro all human acute myelogenous leukemia (AML) and acute lymphocytic leukemia (ALL) cell lines with MLL rearrangements (MLLr) tested were sensitive to CYC065 and that the drug inhibited MLL-driven gene expression. Potent anticancer activity of CYC065 was demonstrated in vivo in AML xenograft models resulting in over 90% inhibition of tumor growth. The data were presented at the 2014 Society of Hematologic Oncology (SOHO) meeting taking place September 17-20, 2014 in Houston, Texas. CYCC: 0.62 (-0.01), CYCCP: 6.47 (-0.22)
Cyclacel Pharmaceuticals hires Dr Samuel L. Barker to board
M2 - Fri Sep 12, 7:51AM CDT
Biopharmaceutical company Cyclacel Pharmaceuticals (NasdaqGM:CYCC) (NasdaqCM:CYCCP) said on Thursday that it has elected Dr Samuel L. Barker, PhD to its board of directors.
CYCC: 0.62 (-0.01), CYCCP: 6.47 (-0.22)
Cyclacel Pharmaceuticals Appoints Samuel L. Barker, Ph.D., to Board of Directors
GlobeNewswire - Thu Sep 11, 6:00AM CDT
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company"
announced today the appointment of Samuel L. Barker, Ph.D., to its Board of Directors. CYCC: 0.62 (-0.01), CYCCP: 6.47 (-0.22)
Cyclacel Announces Abstract Selected for Presentation at Society of Hematologic Oncology Annual Meeting
GlobeNewswire - Wed Sep 10, 6:08AM CDT
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company"
, a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, announced that an abstract highlighting the therapeutic potential of CYC065, the Company's novel, orally available, second generation cyclin-dependent kinase (CDK) inhibitor, in acute myeloid leukaemia (AML) and mixed-lineage leukaemia (MLL), has been selected for presentation at the Society of Hematologic Oncology (SOHO) annual meeting, taking place September 17-20, 2014 at the Hilton Americas Hotel in Houston, Texas. CYCC: 0.62 (-0.01), CYCCP: 6.47 (-0.22)
Cyclacel Pharmaceuticals to Present at 16th Rodman & Renshaw Annual Global Investment Conference
GlobeNewswire - Tue Sep 02, 6:10AM CDT
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company"
, a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders today announced that the Company will present at the 16 Rodman & Renshaw Annual Global Investment Conference being held at the New York Palace Hotel, New York, NY. Spiro Rombotis, President & Chief Executive Officer, will provide an overview of the Company and its progress in key programs at 10:25 am EDT on Tuesday September 9, 2014. CYCC: 0.62 (-0.01), CYCCP: 6.47 (-0.22)
Cyclacel Pharmaceuticals Reports Second Quarter 2014 Financial Results
GlobeNewswire - Tue Aug 12, 4:41PM CDT
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company"
, a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today reported its financial results and business highlights for the second quarter ended June 30, 2014. CYCC: 0.62 (-0.01), CYCCP: 6.47 (-0.22)
Cyclacel Pharmaceuticals to Release 2014 Second Quarter Financial Results
GlobeNewswire - Wed Aug 06, 6:00AM CDT
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company"
, a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, will announce financial results for the second quarter ended June 30, 2014 on Tuesday, August 12, 2014. The Company will host a conference call and live webcast at 4:30 pm Eastern time on the same day. CYCC: 0.62 (-0.01), CYCCP: 6.47 (-0.22)
Cyclacel Pharmaceuticals to Present at 9th Annual JMP Securities Healthcare Conference
GlobeNewswire - Tue Jun 17, 3:05PM CDT
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company"
, a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders today announced that the Company will present at the 9 Annual JMP Securities Healthcare Conference being held at The Westin New York Grand Central, New York City. Paul McBarron, Executive Vice President, Finance and Chief Operating Officer, will provide an overview of the Company and its progress in key programs at 11:00 a.m. EDT on Tuesday, June 24, 2014. CYCC: 0.62 (-0.01), CYCCP: 6.47 (-0.22)
